Welcome to LookChem.com Sign In|Join Free
  • or

73963-72-1

Post Buying Request

73963-72-1 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Cilostazol
Cas No: 73963-72-1
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
High quality Cilostazol supplier in China
Cas No: 73963-72-1
No Data No Data Metric Ton/Day Simagchem Corporation Contact Supplier
High purity Cilostazol with good quality
Cas No: 73963-72-1
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier
Cilostazol CAS No.73963-72-1
Cas No: 73963-72-1
No Data 1 Gram 1000 Kilogram/Month Hangzhou JINLAN Pharm-Drugs Technology Co., Ltd Contact Supplier
Factory supply Cilostazol Cas 73963-72-1 with top quality and fast delivery
Cas No: 73963-72-1
No Data 1 Kilogram 15 Metric Ton/Year Wuhan Fortuna Chemical Co.,Ltd Contact Supplier
High Quality 99% Cilostazol 73963-72-1 GMP Manufacturer
Cas No: 73963-72-1
USD $ 0.1-0.1 / Gram 1 Gram 100 Metric Ton/Year Xi'an Xszo Chem Co., Ltd. Contact Supplier
Factory Supply Cilostazol
Cas No: 73963-72-1
No Data 1 1 Ality Chemical Corporation Contact Supplier
Cilostazol
Cas No: 73963-72-1
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one
Cas No: 73963-72-1
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
Cilostazol
Cas No: 73963-72-1
USD $ 1.0-1.0 / Kilogram 1 Kilogram 1000 Metric Ton/Year Henan Sinotech Import&Export Corporation Contact Supplier

73963-72-1 Usage

Side effects

There may be occasionally rash, hives, itching, palpitations, pulse frequency, low blood pressure, fever, dizziness, dizziness, vertigo, insomnia or drowsiness, swelling, pain, fatigue, weakness, stomach discomfort, nausea, vomiting, loss of appetite, diarrhea, upper abdominal pain, abdominal fullness, increased level of GOT (serum alanine aminotransferase), ALP (serum alkaline phosphatase), LDH (serum lactate dehydrogenase), BUN (blood urea nitrogen), creatinine and uric acid, gastrointestinal bleeding, epistaxis, subcutaneous bleeding, retinal hemorrhage, hematuria, bleeding tendencies and thrombocytopenia. The above information is edited by the chemicalbook of Dai Xiongfeng.

Biological Activity

Potent phosphodiesterase III A (PDE3A) inhibitor (IC 50 = 0.2 μ M) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo . Also affects lipid levels in vivo .

Clinical Use

Cilostazol, a quinolinone derivative, is a potent orally active antiplatelet drug approved for the treatment of intermittent claudication (a peripheral artery disease resulting from blockage of blood vessels in the limbs).

Chemical Properties

It is colorless, needle-like crystals obtained from methanol with the m.p. being 159.4~160.3 ℃ and the UV absorption maximum (methanol) being 257nm (ε15200). It is easily soluble in acetic acid, chloroform, N-methyl-2-pyrrolidone or dimethyl sulfoxide and almost insoluble in ether, water, 0.1mol/L hydrochloric acid or 0.1mol/L sodium hydroxide.

Description

Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand epinephrine-induced platelet aggregation. Side effects include headache and tachycardia.

Definition

ChEBI: A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substiuted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group.

Uses

It can significantly inhibit the platelet aggregation caused by various inducers and aggregates and can dissociate the aggregates without causing secondary aggregation. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. It can also be used for treating ischemic diseases such as chronic arterial occlusive ulcer, pain and coldness.

Uses

A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogeni, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo

Mechanism of action

Cilostazol exhibits greater selectivity than dipyridamole as an inhibitor of PDE3A. The drug does not affect the other PDEs (PDEs 1, 2, or 4). Cilostazol reversibly inhibit platelet aggregation induced by a number of stimuli, such as thrombin, ADP, collagen, or stress from exercise. Additionally, cilostazol inhibits adenosine uptake, leading to increased activity of adenosine at A1 and A2 receptors.

Precautions

Patients of hemophilia, capillary fragility syndrome, upper gastrointestinal bleeding and urinary tract bleeding as well as vitreous hemorrhage should be disabled. Women of pregnancy or possible pregnancy should be disabled. This product is should be taken cautious when being applied to patients in the use of anticoagulants (warfarin) or antiplatelet drugs (aspirin, Ticlid) patients. When using cilostazol, the patients should be subject to blood coagulation performance test. Women in menstrual period, patients of bleeding tendency or with severe hepatic and renal dysfunction as well as elderly should administer with caution; breast-feeding women should avoid breast-feeding.

Metabolism

Cilostazol is rapidly absorbed after oral administration, particularly with a high-fat meal, which greatly increases its bioavailability to approximately 90%. It is extensively metabolized in the liver by various cytochromes. The most important cytochromes appear to be CYP3A4 and, to lesser extent, by CYP2C19, with an elimination half-life of approximately 11 to 13 hours. Among the various metabolites produced (11 metabolites are known), the two major metabolites are 3,4-dehydrocilostazol and 4′-trans-hydroxycliostazol. These two metabolites are pharmacologically active. Studies indicate that the concomitant administration of cilostazol with CYP3A inhibitors can greatly increase cilostazol blood concentrations, and a dose reduction may be required. Similar results are seen when CYP2C19 is inhibited, leading to decreased formation of 4-trans-hydroxycliostazol and significant increases in cilostazol and 3,4-dehydrocilostazol.

Uses

antibacterial; LD50(iv) 280mg/kg(mouse)

Clinical application

It can be used to alleviate the ischemic symptom such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. It can also be applied to the adjuvant treatment of atherosclerosis, arteritis, thromboangiitis obliterans, diabetes-induced ischemia of extremity and takayasu arteritis. Cilostazol also be used as a complementary therapy after surgical treatment to help alleviate the symptoms, improve the circulation and inhibiting thrombosis in transplanted blood vessel.

Brand name

Pletal (Otsuka);Reta.

Production method

Take 5-chloro-N-cyclohexyl pentanamide as the raw material. Under ice-cooling, to 15 mL of benzene solution containing 1.75g ??5-chloro-N-cyclohexyl-pentyl amide solution, slowly add 1.9 g of phosphorus pentachloride and stir at room temperature for 1h. At room temperature and stirring, add 1.4mol/L HN3 to 1 mL of the benzene solution. After stirring overnight, continue the reflux for 2h. The solvent was distilled off under reduced pressure with the residue being poured into ice water and subject to chloroform extraction. The extract was successively washed with water, dilute sodium bicarbonate solution and water, further dried by anhydrous sodium sulfate. After the chloroform was distilled off, the residue was subject to isopropanol-water recrystallization to obtain 1.7 g of 5-(4-chlorobutyl)-l-cyclohexyl-tetrazole, being as colorless needle-like crystals with the yield being 87% and the m.p. being 48-49 ℃. Dissolve 3.2 g 6-hydroxy-3, 4-dihydrogen-2(1H)-quinolinone and 1.4 g of potassium hydroxide in 20 mL of isopropanol. Under reflux, add drop wise of the isopropanol solution containing 5.7 g of the tetrazole obtained above. Continue stirring and reflux for 4h. Evaporate to dryness with the residue being extracted with chloroform. The extract was washed with l mol/L sodium hydroxide solution, dilute hydrochloric acid and water, dried by anhydrous sodium sulfate. Chloroform was distilled off with the residual liquid being subject to chromatograph on silica gel. Use chloroform-methanol (30: 1) for elution. Then apply methanol-water recrystallization to obtain 6.0 g of colorless needles cilostazol with the yield being 74% and the melting point being 158 ??~ 159 ℃.

Pharmacological effects

Cilostazol is commonly used clinically anti-platelet and anti-clotting drugs. It belongs to a phosphodiesterase inhibitor and can inhibit the activity of phosphodiesterase of platelet and smooth muscle cells, leading to increase of the cAMP concentration in platelets and vascular smooth muscle. It can significantly inhibit the platelet aggregation induced by various kinds of aggregation inducers, and can cause the dissociation of the aggregates. Its major metabolite, epoxide has a three to four fold activity of the prototype drug. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. Artery injection of this product can increase the blood flow rate with the strongest effect on the peripheral blood vessels but the weakest effect on the cerebral blood vessels. This product is rapidly absorbed in the intestine after oral administration with the Tmax being 3h, PPB being about 95%. Consecutive administration of four days by twice per day caused no increase in the plasma concentration accumulation. It has good tissue distribution with especially high level in the stomach, liver and kidney. At 72h after administration, 42.75% of the administered drug is excreted via urine and 61.7% is subject to fecal excretion. After 48 hour of administration, bile excretion rate is 31.7%. T1/2α is 2.2h and T1/2β is 18h.

Originator

Otsuka (Japan)

Chemical Properties

Colourless Needles
InChI:InChI=1/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

73963-72-1 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (C2587)  Cilostazol  >98.0%(HPLC) 73963-72-1 1g 490.00CNY Detail
TCI America (C2587)  Cilostazol  >98.0%(HPLC) 73963-72-1 5g 1,390.00CNY Detail
Sigma-Aldrich (PHR1503)  Cilostazol  pharmaceutical secondary standard; traceable to USP 73963-72-1 PHR1503-1G 1,293.67CNY Detail
USP (1134153)  Cilostazol  United States Pharmacopeia (USP) Reference Standard 73963-72-1 1134153-200MG 11,664.90CNY Detail

73963-72-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name cilostazol

1.2 Other means of identification

Product number -
Other names PLETAAL

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:73963-72-1 SDS

73963-72-1Synthetic route

cilostazol bisulfate
877303-65-6

cilostazol bisulfate

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With sodium hydroxide In chloroform; water Product distribution / selectivity;98.7%
cilostazol oxalate
877303-63-4

cilostazol oxalate

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With sodium hydroxide In chloroform; water Product distribution / selectivity;97.9%
cilostazol malate
877303-64-5

cilostazol malate

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With sodium hydroxide In chloroform; water Product distribution / selectivity;97.8%
C20H26BrN5O2

C20H26BrN5O2

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With tetrakis(triphenylphosphine) palladium(0); N-ethyl-N,N-diisopropylamine In acetonitrile for 10h; Reagent/catalyst; Solvent; Temperature; Inert atmosphere; Reflux;96%
3,4-dihydro-6-hydroxy-2(1H)-quinolinone
54197-66-9

3,4-dihydro-6-hydroxy-2(1H)-quinolinone

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole
73963-42-5

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With potassium carbonate; sodium hydroxide; sodium sulfite In ethanol for 8h; Reflux;92.5%
With potassium carbonate; sodium hydroxide; sodium sulfite In water at 92℃; for 6h; Solvent; Reagent/catalyst; Temperature;91.5%
With potassium hydroxide In ethanol at 80℃; for 12h; Solvent; Reagent/catalyst; Temperature; Inert atmosphere; Sealed tube;90%
3,4-dihydro-6-hydroxy-2(1H)-quinolinone
54197-66-9

3,4-dihydro-6-hydroxy-2(1H)-quinolinone

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole
73963-42-5

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole

A

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one
865792-18-3

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one

B

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

C

OPC 13015
73963-62-9

OPC 13015

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In ethanol at 75 - 80℃;A n/a
B 89%
C n/a
C20H26ClN5O2

C20H26ClN5O2

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With bis(triphenylphosphine)nickel(II) chloride; N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 25℃; for 8h; Inert atmosphere;88%
C20H26IN5O2

C20H26IN5O2

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With bis(triphenylphosphine)nickel(II) chloride; N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 25℃; for 8h; Inert atmosphere;85%
1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole
73963-42-5

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
Stage #1: 3,4-dihydro-6-hydroxy-2(1H)-quinolinone With 1,8-diazabicyclo[5.4.0]undec-7-ene In ethanol for 6.5h; Heating / reflux; Molecular sieve;
Stage #2: 1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole In ethanol for 6.5h; Product distribution / selectivity; Heating / reflux;
40.2%
Multi-step reaction with 4 steps
1: sodium hydroxide / butan-1-ol / 8 h / Reflux
2: iron; ammonium chloride; acetic acid / methanol; water / 5 h / 45 °C / Reflux
3: triethylamine / dichloromethane / 3 h / 0 °C
4: N-ethyl-N,N-diisopropylamine; tetrakis(triphenylphosphine) palladium(0) / acetonitrile / 10 h / Inert atmosphere; Reflux
View Scheme
4-methoxy-aniline
104-94-9

4-methoxy-aniline

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: potassium carbonate / acetone / 0.5 h
2: aluminum (III) chloride / N,N-dimethyl acetamide / 2 h / 150 °C
3: potassium hydroxide / ethanol / 12 h / 80 °C / Inert atmosphere; Sealed tube
View Scheme
3-bromo-4-nitrophenol
5470-65-5

3-bromo-4-nitrophenol

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: sodium hydroxide / butan-1-ol / 8 h / Reflux
2: iron; ammonium chloride; acetic acid / methanol; water / 5 h / 45 °C / Reflux
3: triethylamine / dichloromethane / 3 h / 0 °C
4: N-ethyl-N,N-diisopropylamine; tetrakis(triphenylphosphine) palladium(0) / acetonitrile / 10 h / Inert atmosphere; Reflux
View Scheme
C17H22BrN5O3

C17H22BrN5O3

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: iron; ammonium chloride; acetic acid / methanol; water / 5 h / 45 °C / Reflux
2: triethylamine / dichloromethane / 3 h / 0 °C
3: N-ethyl-N,N-diisopropylamine; tetrakis(triphenylphosphine) palladium(0) / acetonitrile / 10 h / Inert atmosphere; Reflux
View Scheme
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

oxalic acid
144-62-7

oxalic acid

cilostazol oxalate
877303-63-4

cilostazol oxalate

Conditions
ConditionsYield
In acetone at 20 - 25℃; for 3h;97%
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

cilostazol bisulfate
877303-65-6

cilostazol bisulfate

Conditions
ConditionsYield
With sulfuric acid In Isopropyl acetate at 20 - 25℃; for 3h; Product distribution / selectivity;94%
With sulfuric acid In acetone at 20 - 25℃; for 3h;92%
With sulfuric acid In butanone at 20 - 25℃; for 3h; Product distribution / selectivity;91%
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

maleic acid
110-16-7

maleic acid

cilostazol malate
877303-64-5

cilostazol malate

Conditions
ConditionsYield
In acetone at 20 - 25℃; for 3h;90%
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

ethyl iodide
75-03-6

ethyl iodide

6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-1-ethyl-3,4-dihydroquinolin-2(1H)-one

6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-1-ethyl-3,4-dihydroquinolin-2(1H)-one

Conditions
ConditionsYield
Stage #1: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril With sodium hydride In mineral oil at 0℃; for 0.5h; Inert atmosphere;
Stage #2: ethyl iodide In mineral oil at 0 - 20℃; for 12h; Inert atmosphere;
81%
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

A

OPC-13326
93632-84-9

OPC-13326

3,4-Dihydro-6-<4-<1-(cis-2-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone
87153-03-5, 87153-05-7

3,4-Dihydro-6-<4-<1-(cis-2-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone

3,4-Dihydro-6-<4-<1-(trans-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone
98360-32-8, 98360-33-9

3,4-Dihydro-6-<4-<1-(trans-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone

3,4-Dihydro-6-<4-<1-(cis-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone
98360-32-8, 98360-33-9

3,4-Dihydro-6-<4-<1-(cis-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone

E

OPC 13213
87153-04-6

OPC 13213

F

OPC 13217
87153-06-8

OPC 13217

Conditions
ConditionsYield
metabolism studies, pharmacokinetic;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole
73963-42-5

1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one
865792-18-3

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one

Conditions
ConditionsYield
With sodium hydride In DMF (N,N-dimethyl-formamide) at 10 - 15℃; for 27.5h;
4-bromo-3-(bromomethyl)butanoyl chloride
1227960-59-9

4-bromo-3-(bromomethyl)butanoyl chloride

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

1-(4-Bromo-3-(bromomethyl)butanoyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
1227960-58-8

1-(4-Bromo-3-(bromomethyl)butanoyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one

Conditions
ConditionsYield
With triethylamine; dmap In tetrahydrofuran at 0 - 20℃; Inert atmosphere;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Conditions
ConditionsYield
With iodine In 2-methyl-propan-1-ol at 24.84 - 119.84℃; Kinetics; Solvent; Temperature;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

2,3-dicyano-5,6-dichloro-p-benzoquinone
84-58-2

2,3-dicyano-5,6-dichloro-p-benzoquinone

C28H26ClN7O4

C28H26ClN7O4

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

2,3-dicyano-5,6-dichloro-p-benzoquinone
84-58-2

2,3-dicyano-5,6-dichloro-p-benzoquinone

CLZ-DDQ
1266615-52-4

CLZ-DDQ

Conditions
ConditionsYield
In acetonitrile for 298 - 313h; Kinetics; Solvent; Temperature;
2,5-dihydroxybenzoic acid.
490-79-9

2,5-dihydroxybenzoic acid.

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

cilostazol gentisic acid
1352614-11-9

cilostazol gentisic acid

Conditions
ConditionsYield
In butanone at 20 - 50℃; for 120h; Solvent; Temperature; Time; Concentration;
In acetone at 20 - 40℃; for 168h;
2,5-dihydroxybenzoic acid.
490-79-9

2,5-dihydroxybenzoic acid.

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

cilostazol gentisic acid monohydrate
1352614-12-0

cilostazol gentisic acid monohydrate

Conditions
ConditionsYield
With water In nitromethane at 20 - 50℃; for 120h; Time;
4-hydroxysalicylic acid
89-86-1

4-hydroxysalicylic acid

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

cilostazol 2,4-dihydroxybenzoic acid
1352614-14-2

cilostazol 2,4-dihydroxybenzoic acid

Conditions
ConditionsYield
In nitromethane at 20 - 50℃; for 120h; Solvent; Temperature; Time; Concentration;
In acetone at 20℃; for 168h;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

4-hydroxy-benzoic acid
99-96-7

4-hydroxy-benzoic acid

cilostazol 4-hydroxybenzoic acid
1352614-13-1

cilostazol 4-hydroxybenzoic acid

Conditions
ConditionsYield
In nitromethane at 20 - 50℃; for 120h; Solvent; Temperature; Time; Concentration;
In acetone at 20℃; for 168h;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

heptakis-(2,3,6-tris-(2-hydroxypropyl))-β-cyclodextrin
128446-35-5

heptakis-(2,3,6-tris-(2-hydroxypropyl))-β-cyclodextrin

2C105H196O56*C20H27N5O2

2C105H196O56*C20H27N5O2

Conditions
ConditionsYield
In ethanol; water at 30℃;
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
73963-72-1

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

C29H38N6O3S

C29H38N6O3S

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: sodium hydride / mineral oil / 0.5 h / 0 °C / Inert atmosphere
1.2: 12 h / 0 - 20 °C / Inert atmosphere
2.1: 1,1,3,3-Tetramethyldisiloxane; bis(triphenylphosphine)carbonyliridium(I) chloride / dichloromethane / 0.5 h / 20 °C
2.2: 3 h / 20 °C
View Scheme
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 73963-72-1